One Stop Hurtles on Newest Contract
One Stop Systems, Inc. (NASDAQ: OSS) began Thursday sharply in the green. The Escondido, Calif.-based company, claiming to be a leader in rugged Enterprise Class compute for artificial intelligence (AI), machine learning (ML) and sensor processing at the edge, today announced a new $2 million production contract from a breakthrough medical imaging OEM advancing non-invasive breast cancer screening. OSS expects the total program value of at least $25 million over the next five years.Under the terms of the contract, OSS will provide 65 next-generation liquid-cooled 3U-SDS that have become standard on all the OEM’s Breast Scanning devices. OSS expects to recognize revenue from this contract over the next six to 12 months. This order represents a transition from successful pilot to volume production, following an initial $500,000 development-phase order in March 2025.“We are excited to deepen our relationship with this leading medical OEM customer and support their expanding production,” stated CEO Mike Knowles. “Their advanced imaging system relies on machine learning algorithms running in real-time. Meeting their demanding requirements including rugged reliability, GPU performance, small form factor, and minimal noise, highlights the unmatched capability of our Enterprise Class, edge-computing platforms.”OSS shares began trading Thursday up 31 cents, or 7.8%, to $4.30.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


